Auris Medical to Host Key Opinion Leader Event Focused on Clinical-Stage Pipeline on June 16 in New York City
May 31 2017 - 8:01AM
- Program to highlight AM-125 for vertigo and upcoming Phase 3
data readouts for AM-111 and Keyzilen®
- Featured presentation by Dr. Elias Michaelides, Yale School of
Medicine
Zug, Switzerland, May 31, 2017 - Auris Medical
Holding AG (NASDAQ: EARS), a clinical-stage company dedicated to
developing therapeutics that address important unmet medical needs
in neurotology, today announced that it will host a Key Opinion
Leader event on Friday, June 16, 2017, at 8 am EDT in New York
City. The event will focus on Auris Medical's clinical-stage
pipeline and feature a presentation by Elias Michaelides, MD,
Associate Professor of Surgery, Otolaryngology and Director of the
Hearing and Balance Program at the Yale School of Medicine.
To reserve a seat, please contact Cindy McGee via
e-mail at investors@aurismedical.com. A live webcast will be
available through the Events and Presentations page in the
Investors section of the Auris Medical website at
www.aurismedical.com and a replay of the presentation will be
available following the event.
Auris Medical's clinical-stage development pipeline
includes AM-111 for acute inner ear hearing loss, Keyzilen®
(AM-101) for acute inner ear tinnitus and AM-125 for the intranasal
treatment of vertigo. Auris Medical is currently enrolling patients
in two Phase 3 clinical trials of AM-111, with top-line results
from the HEALOS trial expected in the fall of 2017. Auris Medical
is also enrolling patients in the TACTT3 trial of Keyzilen®
(AM-101) and expects to announce top-line results in the first
quarter of 2018. In addition, Auris Medical will initiate a Phase 1
trial of AM-125 in 2017.
About Auris Medical
Auris Medical is a Swiss biopharmaceutical company
dedicated to developing therapeutics that address important unmet
medical needs in neurotology. The Company is focused on the Phase 3
development of treatments for acute inner ear hearing loss (AM-111)
and for acute inner ear tinnitus (Keyzilen®; AM-101) by way of
intratympanic administration with biocompatible gel formulations.
In addition, Auris Medical is developing intranasal betahistine for
Meniere's disease and vestibular vertigo (AM-125) as well as
early-stage research and development projects. The Company was
founded in 2003 and is headquartered in Zug, Switzerland. The
shares of Auris Medical Holding AG trade on the NASDAQ Global
Market under the symbol "EARS."
Forward-looking Statements
This press release may contain statements that
constitute "forward-looking statements" within the meaning of
Section 27A of the Securities Act of 1933 and Section 21E of the
Securities Exchange Act of 1934. Forward-looking statements are
statements other than historical fact and may include statements
that address future operating, financial or business performance or
Auris Medical's strategies or expectations. In some cases, you can
identify these statements by forward-looking words such as "may,"
"might," "will," "should," "expects," "plans," "anticipates,"
"believes," "estimates," "predicts," "projects," "potential,"
"outlook" or "continue," and other comparable terminology.
Forward-looking statements are based on management's current
expectations and beliefs and involve significant risks and
uncertainties that could cause actual results, developments and
business decisions to differ materially from those contemplated by
these statements. These risks and uncertainties include, but are
not limited to, prevailing market conditions, whether the Company
will consummate the offering of shares and warrants on the expected
terms, or at all, the satisfaction of closing conditions related to
the offering and risks related to the application of the net
proceeds, if any, from the offering. There can be no assurance that
the Company will be able to complete the offering at the
anticipated size or on the anticipated terms, or at all. In any
event, the Company may continue to need additional funding and may
be unable to raise capital when needed, which could force the
Company to delay, reduce or eliminate its product development
programs or commercialization efforts. Other risks and
uncertainties relating to the Company's business include the timing
and conduct of clinical trials of Auris Medical's product
candidates, including the likelihood that the TACTT3 clinical trial
with Keyzilen® will not meet its endpoints, the clinical utility of
Auris Medical's product candidates, the timing or likelihood of
regulatory filings and approvals, Auris Medical's intellectual
property position and Auris Medical's financial position, including
the impact of any future acquisitions, dispositions, partnerships,
license transactions or changes to Auris Medical's capital
structure, including future securities offerings. These risks and
uncertainties also include, but are not limited to, those described
under the caption "Risk Factors" in Auris Medical's Annual Report
on Form 20-F and future filings with the Securities and Exchange
Commission. Forward-looking statements speak only as of the date
they are made, and Auris Medical does not undertake any obligation
to update them in light of new information, future developments or
otherwise, except as may be required under applicable law. All
forward-looking statements are qualified in their entirety by this
cautionary statement.
Company contact: Cindy McGee, Head of Investor
Relations and Corporate Communications, +41 61 201 1350,
investors@aurismedical.com
Media contact: David Schull, Russo Partners,
1-858-717-2310,david.schull@russopartnersllc.com
Auris Medical (NASDAQ:EARS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Auris Medical (NASDAQ:EARS)
Historical Stock Chart
From Apr 2023 to Apr 2024